Neuromagen Pharma secured funding

Another investment is an Oazis-grown startup!

Neuromagen Pharma developing a new class of drugs for neurodegenerative diseases.
Their drugs have been shown to slow #alzheimers, #ALS, and other degenerative diseases in mice get funding to start trials.

Here is more information about it:

Neuromagen was established during Oazis' second cohort after Gil Ben-Menachem the CEO join forces with Esther Priel the researcher beyond this technology and their associate Daniella Bouhnik.
A special thank you to their amazing mentor Dr. Helena Grinberg-Rashi